All News

pso.PsA_.NPF_.jpg

Updates in Psoriatic Arthritis at EULAR 2022

Antoni Chan, MD, PhD

At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.

Read Article
Conv3.jpg

EULAR 2022 Featured Industry Abstracts

Jack Cush, MD

Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.

Read Article
psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis

Jack Cush, MD

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

Jack Cush, MD

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

Jack Cush, MD

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A

Read Article
TNR,controversies,psa

TNR - Controversies in PsA

Jack Cush, MD

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:

Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

Read Article
2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt
Richard Conway RichardPAConway ( View Tweet)
Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
David Liew drdavidliew ( View Tweet)
Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by pt factors - pt global and pain, skin, joints, CRP, function drove the data. Ask pt and treat what is treatable. #OP0025 @eular @RheumNow https://t.co/x4T6sPEi8o
Janet Pope Janetbirdope ( View Tweet)
in case you're interesting in the causal diagram for the mediation modelling for this: far from proven, but certainly does raise some questions about a potential advantage of IL-23 inhibitors in a crowded PsA market #EULAR2022 @RheumNow https://t.co/bSuE3tDHUO
David Liew drdavidliew ( View Tweet)
Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3 Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking! POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
David Liew drdavidliew ( View Tweet)
How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/function, joint manifestations, and skin involvement accounted for 62% of variability in fatigue. How do we account for the other 38%? @RheumNow #EULAR2022 ABST#OP0025

Robert B Chao, MD doctorRBC ( View Tweet)

Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS

Links:

Richard Conway RichardPAConway ( View Tweet)
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011, Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96

Links:

Dr. John Cush RheumNow ( View Tweet)

ABP 654 is a Ustekinumab (anti-IL-12/23) biosimilar from Amgen - 563 pt, phase 3 trial shown to be equivalent to originator in mod- severe plaque psoriasis (no meaningful differences). ABP 654 is also being developed for Crohns & UC. https://t.co/vDNfMXCWcC

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×